文献速递冠心病

替格瑞洛与氯吡格雷在老年ACS患者PCI术后的疗效与安全性比较

[The efficacy and safety of ticagrelor versus clopidogrel in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2021-01-01

替格瑞洛组缺血事件和全因死亡发生率更低,BARC 2、3、5型出血无显著差异。

要点

  • 老年ACS患者PCI术后替格瑞洛组2年缺血事件发生率3.2%低于氯吡格雷组5.6%。
  • 替格瑞洛组全因死亡1.5%低于氯吡格雷组4.1%,校正后HR=0.402。
  • 两组BARC 2、3、5型出血发生率差异无统计学意义。

核心结论

  • 真实世界中老年ACS患者PCI术后应用替格瑞洛与长期缺血事件及全因死亡风险降低相关,且不增加出血风险。

主要发现

  • 校正混杂因素后,替格瑞洛组缺血事件HR=0.637(95%CI 0.409~0.991,P=0.046),全因死亡HR=0.402(95%CI 0.213~0.758,P=0.005)。
  • 校正后BARC 2、3、5型出血风险HR=0.957(95%CI 0.496~1.848,P=0.897)。

关键数值与推荐

  • 主要终点为PCI术后2年缺血事件,即心原性死亡、心肌梗死和/或缺血性卒中的复合终点。
  • 次要终点为2年全因死亡和BARC 2、3、5型出血事件。

临床怎么用

  • 对年龄≥65岁行PCI的ACS患者,替格瑞洛可能作为优先选择的P2Y12受体抑制剂以降低缺血事件和全因死亡。
  • 选择替格瑞洛时需个体化评估缺血与出血风险,本研究显示不增加BARC 2、3、5型出血。

局限性

  • 本研究为单中心回顾性队列研究的post-hoc分析,可能存在选择偏倚和残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the efficacy and safety of ticagrelor and clopidogrel in elderly Chinese patients with acute coronary syndrome (ACS) underwent percutaneous coronary intervention (PCI) in the real world. Methods: This study is a post-hoc analysis of a single center, retrospective cohort study. Between March 2016 and March 2018, elderly (age≥65) ACS patients who underwent PCI in the General Hospital of Northern Theater Command were included in the study. The patients were grouped according to P2Y12 receptor inhibitor. The primary endpoints of this study were ischemic events during the 2-year follow-up, which were defined as the composite of cardiac death, myocardial or stroke. The secondary efficiency endpoints included all-cause death and BARC 2, 3, 5 bleeding events. Results: A total of 4 022 elderly (mean age: (71.5±5.3) years) ACS patients were included in this study. Based on the choice of P2Y12 receptor inhibitor, patients were divided into clopidogrel (n=3 201) and ticagrelor (n=821) groups. Incidences of ischemic events (3.2% (26/821) vs. 5.6% (179/3 201), P=0.005) at 2 years were significantly lower in ticagrelor group compared to clopidogrel group. BARC 2, 3, 5 bleeding events (1.7% (14/821) vs. 1.6% (52/3 201), P=0.818) were comparable between the two groups. The incidence of all-cause death (1.5% (12/821) vs. 4.1% (132/3 201), P=0.005) were also lower in the ticagrelor group compared to the clopidogrel group. Clinical outcomes were consistent after adjusting for confounding factors, the incidence of ischemic events (HR= 0.637, 95%CI 0.409-0.991, P=0.046) and all-cause mortality (HR=0.402, 95%CI 0.213-0.758, P=0.005) was significantly lower in the ticagrelor group compared with the clopidogrel group. Risk of BARC 2, 3, 5 bleeding events were similar between the two groups (HR=0.957, 95%CI 0.496-1.848, P=0.897). Conclusion: In real-world clinical practice, for elderly patients with ACS undergoing PCI, ticagrelor use might reduce the incidence of long-term ischemic events and all-cause death without increasing the risk of bleeding. 目的: 评估真实世界中老年急性冠状动脉综合征(ACS)患者在经皮冠状动脉介入治疗(PCI)术后使用替格瑞洛和氯吡格雷的长期有效性和安全性。 方法: 本研究为一项单中心、回顾性队列研究,选取2016年3月至2018年3月在北部战区总医院心血管内科住院并接受PCI治疗的老年(年龄≥65岁)ACS患者,依据患者术后服用的P2Y12受体抑制剂种类分为氯吡格雷组和替格瑞洛组。本研究的主要终点为PCI术后2年的缺血事件,即包括心原性死亡、心肌梗死和/或缺血性卒中的复合终点。次要终点为2年的全因死亡和出血学术研究联合会(BARC)定义的BARC 2、3、5型出血事件。比较两组患者终点事件的发生情况,采用多因素Cox风险比例模型探讨不同的抗血小板药物对患者预后的影响,并采用Kaplan-Meier法绘制生存曲线。 结果: 共纳入4 022例行PCI治疗的老年ACS患者,年龄为(71.5±5.3)岁,其中氯吡格雷组3 201例,替格瑞洛组821例。与氯吡格雷组相比,接受替格瑞洛治疗的患者2年的缺血事件发生率较低[3.2%(26/821)比5.6%(179/3 201),P=0.005]。两组在2年BARC 2、3、5型出血事件发生率上差异无统计学意义[1.7%(14/821)比1.6%(52/3 201),P=0.818]。接受替格瑞洛治疗的老年患者全因死亡的发生率较使用氯吡格雷者低[1.5%(12/821)比4.1%(132/3 201),P=0.005]。在校正了组间差异后发现,相比于氯吡格雷组,服用替格瑞洛的患者2年缺血事件(HR=0.637,95%CI 0.409~0.991,P=0.046)及全因死亡(HR=0.402,95%CI 0.213~0.758,P=0.005)发生风险更低,BARC 2、3、5型出血发生风险差异无统计学意义(HR=0.957,95%CI 0.496~1.848,P=0.897)。 结论: 在真实世界临床实践中,与氯吡格雷相比,老年ACS患者PCI术后应用替格瑞洛与长期缺血事件及全因死亡风险降低相关,且不增加出血风险。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Na K, Li MY, Qiu MH, et al. [The efficacy and safety of ticagrelor versus clopidogrel in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 34775722. doi:10.3760/cma.j.cn112148-20201127-00943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。